Gyre Therapeutics Inc. (GYRE)vsNovartis AG ADR (NVS)
GYRE
Gyre Therapeutics Inc.
$7.68
+4.49%
HEALTHCARE · Cap: $696.73M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 48428% more annual revenue ($56.58B vs $116.59M). NVS leads profitability with a 23.9% profit margin vs 4.3%. NVS trades at a lower P/E of 21.2x. NVS earns a higher WallStSmart Score of 51/100 (C-).
GYRE
Hold39
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GYRE.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 33.4% year-over-year
Earnings expanding 166.2% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
4.3% margin — thin
Operating margin of 0.3%
Premium valuation, high expectations priced in
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : GYRE
The strongest argument for GYRE centers on Revenue Growth, EPS Growth. Revenue growth of 33.4% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : GYRE
The primary concerns for GYRE are Market Cap, Profit Margin, Operating Margin. A P/E of 381.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
GYRE profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
GYRE carries more volatility with a beta of 6.40 — expect wider price swings.
GYRE is growing revenue faster at 33.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 39/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a cutting-edge biopharmaceutical company dedicated to developing innovative therapies for rare and complex diseases. By utilizing a proprietary platform, Gyre accelerates the discovery and commercialization of precision treatments aimed at addressing significant unmet medical needs. The company's strong focus on scientific excellence and patient-centered outcomes, coupled with its advancing pipeline in gene therapy and precision medicine, positions Gyre for substantial growth within the competitive biopharmaceutical landscape. Through strategic partnerships and a commitment to research, Gyre is poised to make a meaningful impact on the lives of patients facing challenging health conditions.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?